Abacavir/lamivudine/lopinavir/ritonavir - Cipla/Drugs for Neglected Diseases Initiative
Alternative Names: 4-in-1 fixed combination ARV therapy - Cipla/Drugs for Neglected Diseases Initiative Foundation; 4-in-1 paediatric antiretroviral drug combination - Cipla/Drugs for Neglected Diseases Initiative Foundation; Abacavir/lamivudine/lopinavir/ritonavir; Lopinavir/r/lamivudine/abacavir; Lopinavir/ritonavir/3TC/ABC; Lopinavir/ritonavir/3TC/AZT; Lopinavir/ritonavir/lamivudine/abacavir; Lopinavir/ritonavir/lamivudine/zidovudine; LPV/r/ABC/3TC - Cipla/Drugs for Neglected Diseases Initiative Foundation; LPV/r/AZT/3TC - Cipla/Drugs for Neglected Diseases Initiative Foundation; Quadruple fixed combination HIV therapy - Cipla/Drugs for Neglected Diseases Initiative FoundationLatest Information Update: 06 May 2024
At a glance
- Originator Cipla
- Class Amides; Antiretrovirals; Carbamates; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Pyrimidine nucleosides; Pyrimidinones; Small molecules; Thiazoles
- Mechanism of Action HIV protease inhibitors; HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors; PRINS expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II HIV infections
Most Recent Events
- 03 Mar 2024 Pharmacokinetics data from a phase I/II trial in HIV infections presented at the 31th Conference on Retroviruses and Opportunistic Infections (CROI-2024)
- 19 Feb 2023 Pharmacokinetics and adverse events data from a phase I/II trial in HIV infections presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)
- 02 Aug 2019 Drugs for Neglected Diseases announces intention to submit application for registration to the regulatory body for HIV infections in 2019